Developments in the immunotherapy of glomerular disease

Patrick H. Nachman, Jeffrey Martin

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Glomerular diseases span a broad spectrum of clinical syndromes, with varied clinical manifestations, underlying etiologies, and pathogenic mechanisms. They can be secondary to underlying infectious, toxic, environmental, or drug exposures, or present as "primary entities." In the latter case, most glomerular diseases are thought to be due to autoimmune dysregulation, and their treatment is primarily immunosuppressive. The armamentarium for immunomodulation includes corticosteroids, alkylating agents, anti-metabolites, calcineurin inhibitors, and new biological agents designed to block specific inflammatory pathways. The choice of therapy for an individual patient must be based on the specific character of the glomerular disease and its acuity and severity, as well as the patient's comorbidities, history of prior exposure to immunosuppressive drugs, and risk factors for developing complications of the disease or its treatment. The complexities of such therapy can best be addressed by an experienced team of care givers in which the clinical pharmacist can help minimize, if not eliminate, potential sources of drug induced toxicities and adverse effects. This article will describe the major agents and modalities used in the management of the most common glomerular diseases.

Original languageEnglish (US)
Pages (from-to)472-489
Number of pages18
JournalJournal of Pharmacy Practice
Issue number6
StatePublished - Dec 2002
Externally publishedYes

Bibliographical note

Copyright 2020 Elsevier B.V., All rights reserved.


  • Drug treatments
  • Glomerular diseases
  • Immunotherapy


Dive into the research topics of 'Developments in the immunotherapy of glomerular disease'. Together they form a unique fingerprint.

Cite this